Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Capital Expenditures: 2019-2025

Historic Capital Expenditures for Summit Therapeutics (SMMT) over the last 5 years, with Sep 2025 value amounting to $71,000.

  • Summit Therapeutics' Capital Expenditures rose 22.41% to $71,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $565,000, marking a year-over-year increase of 344.88%. This contributed to the annual value of $139,000 for FY2024, which is 8.59% up from last year.
  • Per Summit Therapeutics' latest filing, its Capital Expenditures stood at $71,000 for Q3 2025, which was down 83.18% from $422,000 recorded in Q1 2025.
  • Summit Therapeutics' Capital Expenditures' 5-year high stood at $422,000 during Q1 2025, with a 5-year trough of -$20,000 in Q3 2022.
  • Moreover, its 3-year median value for Capital Expenditures was $53,000 (2023), whereas its average is $76,000.
  • As far as peak fluctuations go, Summit Therapeutics' Capital Expenditures plummeted by 400.00% in 2022, and later soared by 10,450.00% in 2025.
  • Summit Therapeutics' Capital Expenditures (Quarterly) stood at $120,000 in 2021, then crashed by 108.33% to -$10,000 in 2022, then soared by 120.00% to $2,000 in 2023, then soared by 600.00% to $14,000 in 2024, then grew by 22.41% to $71,000 in 2025.
  • Its Capital Expenditures stands at $71,000 for Q3 2025, versus $422,000 for Q1 2025 and $14,000 for Q4 2024.